PIK3CG and gliosarcoma: In the context of existing and emerging therapies, the current study shows that PI3K and BRAF inhibitors could be useful in targeted therapy for gliosarcoma patients, and that the molecular profiling of gliosarcoma could be very helpful to find fitting clinical trials or the off-label use of drugs.